Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
CSL Limited, commonly referred to as CSL, is a global biotechnology leader headquartered in Australia. Founded in 1916, the company has evolved significantly, establishing a strong presence in key operational regions including North America, Europe, and Asia-Pacific. Specialising in the development of innovative therapies for rare and serious diseases, CSL focuses on areas such as immunology, haematology, and respiratory health.
The company is renowned for its core products, including immunoglobulins and clotting factors, which are distinguished by their high quality and efficacy. CSL's commitment to research and development has positioned it as a market leader, with notable achievements such as being consistently ranked among the top biopharmaceutical companies globally. With a rich history and a dedication to improving patient outcomes, CSL continues to set benchmarks in the biotechnology industry.
+7 vs industry average
Csl’s score of 47 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
In 2025, CSL Limited reported total emissions of approximately 286,000,000 kg CO2e, comprising 135,000,000 kg CO2e from Scope 1 and 151,000,000 kg CO2e from Scope 2. The company has set ambitious climate commitments, aiming for a 40% reduction in absolute Scope 1 and 2 emissions by 2030, using the average annual emissions from fiscal years 2019 to 2021 as a baseline. Additionally, CSL has committed to a 42% reduction in absolute Scope 1 and 2 GHG emissions by FY2030 from a FY2021 base year, as part of its Science Based Targets initiative (SBTi) commitments.
CSL's emissions data reflects a consistent focus on sustainability within the pharmaceutical and biotechnology sector, with a commitment to ensuring that 73.1% of its suppliers by emissions will have science-based targets by FY2030. The company continues to enhance its climate strategy, aligning with industry standards to mitigate its environmental impact.
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 2
CSL Ltd. commits to reduce absolute scope 2 GHG emissions 42% by FY2030 from a FY2021 base year.
2030
42% reduction in Scope 1
CSL Ltd. commits to reduce absolute scope 1 GHG emissions 42% by FY2030 from a FY2021 base year.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


Common questions about Csl’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more